G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
Jazyk angličtina Země Spojené státy americké Médium electronic
Typ dokumentu dopisy, randomizované kontrolované studie, práce podpořená grantem
PubMed
35798720
PubMed Central
PMC9262924
DOI
10.1038/s41408-022-00698-2
PII: 10.1038/s41408-022-00698-2
Knihovny.cz E-zdroje
- MeSH
- azacytidin * terapeutické užití MeSH
- faktor stimulující kolonie granulocytů MeSH
- lidé MeSH
- myelodysplastické syndromy * farmakoterapie MeSH
- protinádorové antimetabolity terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- azacytidin * MeSH
- faktor stimulující kolonie granulocytů MeSH
- protinádorové antimetabolity MeSH
GA trial is registered under EudraCT#: 2013-001639-38.
BIOCEV 1st Medical Faculty Charles University Vestec Czech Republic
Cytogenetics 1st Medical Faculty General Hospital and Charles University Prague Czech Republic
Faculty of Mathematics and Physics Charles University Prague Czech Republic
Haematology Clinic General Faculty Hospital Prague Czech Republic
Pathophysiology 1st Medical Faculty Charles University Prague Czech Republic
Zobrazit více v PubMed
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65. doi: 10.1182/blood-2012-03-420489. PubMed DOI PMC
Fenaux P, Gattermann N, Seymour JF, Hellstrom-Lindberg E, Mufti GJ, Duehrsen U, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149:244–9. doi: 10.1111/j.1365-2141.2010.08082.x. PubMed DOI PMC
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32. doi: 10.1016/S1470-2045(09)70003-8. PubMed DOI PMC
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–9. doi: 10.1200/JCO.2009.23.8329. PubMed DOI
Garcia JS, Wei AH, Borate U, Fong CY, Baer MR, Nolte F, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Abstract #656 Presented at the 2020 ASH Annual Meeting 2020.
Zeidan AM, Gracia JS, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z, et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes. Meeting Abstract. 2021 ASCO Annual Meeting I2021.
Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021. PubMed PMC
Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts. Leukemia. 2017;31:2799–806.. doi: 10.1038/leu.2017.159. PubMed DOI PMC
Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahem Q, et al. Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther. 2010;9:1536–43. doi: 10.1158/1535-7163.MCT-10-0191. PubMed DOI PMC
Curik N, Burda P, Vargova K, Pospisil V, Belickova M, Vlckova P, et al. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia. 2012;26:1804–11. doi: 10.1038/leu.2012.47. PubMed DOI
Calip GS, Moran KM, Sweiss KI, Patel PR, Wu Z, Adimadhyam S, et al. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. Cancer. 2019;125:1143–54.. doi: 10.1002/cncr.31914. PubMed DOI PMC
Calip GS, Malmgren JA, Lee WJ, Schwartz SM, Kaplan HG. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. Breast Cancer Res Treat. 2015;154:133–43. doi: 10.1007/s10549-015-3590-1. PubMed DOI PMC
Sapra A, Jaksik R, Mehta H, Biesiadny S, Kimmel M, Corey SJ. Effect of the unfolded protein response and oxidative stress on mutagenesis in CSF3R: a model for evolution of severe congenital neutropenia to myelodysplastic syndrome/acute myeloid leukemia. Mutagenesis. 2020;35:381–9. doi: 10.1093/mutage/geaa027. PubMed DOI PMC
Kakinoki Y, Kubota H, Yamamoto Y. CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin’s lymphoma. Int J Hematol. 2004;79:55–62. doi: 10.1007/BF02983535. PubMed DOI
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25. doi: 10.1182/blood-2005-10-4149. PubMed DOI
